Probiotics as a therapeutic strategy in obesity and overweight: a systematic review
View/ Open
Impact
Scholar |
Other documents of the author: Tomé-Castro, X.M.; Rodriguez-Arrastia, Miguel; Cardona, Diana; Rueda-Ruzafa, Lola; Molina-Torres, Guadalupe; Román, Pablo
Metadata
Show full item recordcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONMetadata
Title
Probiotics as a therapeutic strategy in obesity and overweight: a systematic reviewAuthor (s)
Date
2021Publisher
Wageningen Academic PublishersISSN
1876-2883; 1876-2891Bibliographic citation
Tomé-Castro, X. M., Rodriguez-Arrastia, M., Cardona, D., Rueda-Ruzafa, L., Molina-Torres, G., and Roman, P., 2021. Probiotics as a therapeutic strategy in obesity and overweight: a systematic review. Beneficial Microbes, 1-12. https://doi.org/10.3920/BM2020.0111Type
info:eu-repo/semantics/articlePublisher version
https://www.wageningenacademic.com/doi/abs/10.3920/BM2020.0111Version
info:eu-repo/semantics/submittedVersionSubject
Abstract
Obesity and overweight are two of the most health challenges with an increasing prevalence in recent years, in which several complications have been identified to have a high impact in patients’ health conditions. In ... [+]
Obesity and overweight are two of the most health challenges with an increasing prevalence in recent years, in which several complications have been identified to have a high impact in patients’ health conditions. In this vein, an increasing interest in the gut microbiota has emerged as a target for therapeutic strategies in obesity and overweight due to its direct relation with the aforementioned health conditions and complications. Thus, the aim of this study was to evaluate the efficacy of probiotics as a therapeutic strategy in the management of obesity and overweight. A systematic review of randomised controlled trials was carried out in 6 databases until May 2019 to assess the use of probiotics in obesity and overweight patients. The Jadad Scale was used to assess the quality of the clinical trials. Twenty-three clinical trials published between 2000 and 2019 met the inclusion criteria. The role of probiotics in reducing body mass index and weight as well as changing the visceral abdominal fat area, waist and hip circumference were shown in 14 of 23 trials (60.87%); 14 trials (60.87%) showed changes on patients’ fatty acids and biomarkers; and 4 trials (17.39%) studied the role of the gut microbiota in obese and overweight patients. Some probiotics strains are shown to be effective in reducing body mass index and hip circumference. This review provides evidence of successful results in weight loss using probiotic groups. [-]
Is part of
Beneficial Microbes, 2021Rights
© Wageningen Academic Publishers
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/openAccess
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/openAccess
This item appears in the folowing collection(s)
- MED_Articles [646]